Skip to contentA
Agios Pharmaceuticals, Inc.
A
AGIOAgios Pharmaceuticals, Inc. Q3 2016 · 10-Q
Revenue$8.99M$8.99M+64.0% vs Q3 2015 Net Income-$62.83M-$62.83MN/M vs Q3 2015 EPS Diluted-$1.63-$1.63N/M vs Q3 2015 Operating Income-$63,512,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$52,456,000N/M Margins · derivedOperating margin-706.9%+31.7 pt vs Q3 2015
Net margin-699.3%+35.3 pt vs Q3 2015
ended Sep 30, 2016 · filed Nov 3, 2016 · 34 d after period end